NCT04924478View on ClinicalTrials.gov

Evaluation of Volatile Organic Compounds in Mepolizumab Therapy

UnknownOBSERVATIONAL

Enrollment

60

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Asthma; Eosinophilic

Interventions

BIOLOGICAL

Mepolizumab

Patients will be receiving this treatment as part of their standard clinical care

Trial Locations (1)

SO166YD

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

University Hospital Southampton NHS Foundation Trust

OTHER